Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer

Table 1 Landmark trials for the combination of adjuvant chemotherapy with oxaliplatin and fluoropyrimidines in resected colorectal cancer

Clinical Trial	Regimen	Patients (n/age)	Stage	DFS	OS
				5-yr	6-yr
MOSAIC, 2004	FOLFOX4 vs LV5FU2	2246	II/III	73.3% vs 67.4%	72.9% vs 68.7%
		Age 18-75	40% Stage II		For stage III
		778, > 65 yr (34.6%)			No benefit for stage II at 6-yr and 10-yr
				4-yr	5-yr
NSABP-C-07, 2007	Weekly bolus 5-FU/LV ± Oxaliplatin (FLOX)	2407	II/III	73.2% vs 67.0%	N/A
		396, > 70 yr (16.4%)	695 Stage II (28.8%)		Unplanned subset analyses suggested no benefit for patients > 70 yr (71.6% vs 76.3%)
				7-yr	7-yr
NO16968, 2015	CAPOX (XELOX) vs 5-FU/Leucovorin (C. Mayo/R. Park)	1886	III	63% vs 56%	73% vs 67%
		409, > 70 yr (21.6%)		HR = 0.86 (95%CI: 0.64-1.16)	HR = 0.91 (95%CI: 0.66 TO 1.26)

DFS: Disease free survival; HR: Hazard ratio; OS: Overall survival.